FDA issues a Complete Response Letter to Grace Therapeutics for GTx-104, an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage.
AbbVie Inc. (NYSE:ABBV) is one of the best low volatility stocks to invest in right now. AbbVie Inc. (NYSE:ABBV) announced on April 23 that it received a Complete Response Letter (CRL) from the U.S.
The FDA in July 2025 made publicly available over 200 complete response letters—an initiative that the investment community ...
The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective ...
Pharmaceutical Technology on MSN
FDA issues complete response letter to Replimune’s RP1 for melanoma
Replimune’s RP1 is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.
AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for ...
In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license ...
Although no safety or manufacturing concerns were identified, the agency raised questions regarding the reliability of clinical findings due to inconsistent trial results. The Food and Drug ...
Since the FDA began publishing its rejections of drug approval filings in July last year, companies have become more forthcoming about the details of agency decisions in their own disclosures, ...
Charles River Laboratories International (CRL) recently reported that its virtual control groups in toxicology studies matched traditional control groups on key outcomes, supporting efforts to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results